We describe two patients with psoriasis vulgaris who subsequently developed a subepidermal blistering disease which disclosed IgG and C3 at the basement membrane zone in direct immunofluorescence. The first case was a 75-year-old Japanese man with herpetiform lesions. Histopathology showed neutrophil infiltration. IgG antibodies bound to the dermal side of the salt-split skin. Immunoblot analysis identified a 200-kD antigen in dermal extracts. The second case was a 70-year-old Japanese man. Histopathology showed eosinophil infiltration. IgG antibodies bound to the epidermal side of salt-split skin. Immunoblot analysis identified a 180-kD bullous pemphigoid (BP) antigen in epidermal extracts. We review the clinical and pathological features of psoriatic patients who presented a subepidermal blistering disease in which antigens were detected by immunoblot analysis; i.e., anti-p200 pemphigoid (14 cases) or BP (12 cases). There were few distinct clinical differences between two diseases. However, neutrophils were predominant in anti-p200 pemphigoid, while eosinophils were predominant in BP. After blister formation, ciclosporin was used effectively in addition to systemic steroids in the treatment of anti-p200 pemphigoid. On the other hand, ciclosporin was not used in the treatment of BP with psoriasis.

1.
Chen KR, Shimizu S, Miyakawa S, et al: Coexistence of psoriasis and an usual IgG-mediated subepidermal bullous dermatosis: Identification of a novel 200-kD lower lamina lucida target antigen. Br J Dermatol 1996;134:340–346.
2.
Zillikens D, Kawahara Y, Ishiko A, et al: A novel subepidermal blistering disease with autoantibodies to a 200-kD antigen of the basement membrane zone. J Invest Dermatol 1996;106:465–470.
3.
Endo Y, Tamura A, Ishikawa O, et al: Psoriasis vulgaris coexistent with epidermolysis bullosa acquisita. Br J Dermatol 1997;137:783–786.
4.
Sugi T, Hashimoto T, Hibi T, et al: Production of human monoclonal anti-basement membrane zone (BMZ) antibodies from a patient with bullous pemphigoid (BP) by Epstein-Barr virus transformation. Analysis of heterogeneity of anti-BMZ antibodies in BP sera using them. J Clin Invest 1989;84:1050–1055.
5.
Shirahama S, Furukawa F, Takigawa M: A case of psoriasis vulgaris associated bullae similar to bullous pemphigoid. Proceedings of the 10th Annual Meeting of the Japanese Society for Psoriasis Research (in Japanese), 1995, vol 10, pp 161–162.
6.
Suzuki K, Aoki R: A unique subtype of subepidermal bullous dermatosis in patients with psoriasis vulgaris. Shimada Municipal Hospital Kiyou1998;2:5–9.
7.
Nishioka K, Murata M, Komai R, et al: Bullous pemphigoid-like bullous dermatosis with psoriasis vulgaris (in Japanese). Rinsyo Derma 1998;40:293–296.
8.
Hamada S, Ooido Yuki, Kaneko R, et al: A case of autoimmune bullous disease with 200 kD antigen (in Japanese). Jpn J Dermatol 2001;111:197.
9.
Sawada S, Kawai K, Hashimoto T, et al: A case of autoimmune subepidermal blistering disease (anti-p200 pemphigoid) with psoriatic erythroderma (in Japanese). Rinsyo Derma 2001;43:631–633.
10.
Morris SD, Mallipeddi R, Oyama N, et al: Psoriasis bullosa acquisita. Clin Exp Dermatol 2002;27:665–669.
11.
Hata M, Tokura Y, Nei M, et al: A case of anti p200 pemphigoid coexisting with psoriasis vulgaris (in Japanese). Proceedings of the 17th Annual Meeting of the Japanese Society for Psoriasis Research 2002;17:90.
12.
Hirai A, Hirashima T, Misago N, et al: Autoimmune subepidermal bullous disease (anti-p200 pemphigoid) associated with psoriasis (in Japanese). Nishinihonn J Dermatol 2002;65:517–518.
13.
Habuchi C, Kato Y, Uchida M, et al: A case of bullous disease associated with psoriasis vulgaris (in Japanese). Hifuka no Rinsyo 2003;45:419–422.
14.
Saito M, Nakakita T, Fujimoto H, et al: Autoimmune subepidermal disease associated with psoriasis (in Japanese). Jpn J Dermatol 2003;113:322.
15.
Fukumoto D, Murao K, Takiwaki H, et al: A case of anti-p200 pemphigoid associated with psoriasis (in Japanese). Jpn J Dermatol 2003;113:760.
16.
Perl S, Rappersberger, Fodinger D, et al: Bullous pemphigoid induced by PUVA therapy. Dermatology 1996;193:245–247.
17.
Kirtschig G, Chow ETY, Venning VA, et al: Acquired subepidermal bullous disease associated with psoriasis: A clinical, immunopathological and immunogenetic study. Br J Dermatol 1996;135:738–745.
18.
Kimura J, Iketani T, Soto H, et al: A case of bullous pemphigoid with psoriasis vulgaris (in Japanese). Jpn J Dermatol 1998;108:1183.
19.
Shimizu H, Aoyama Y, Yamada T, et al: A case of psoriasis vulgaris associated with bullous pemphigoid (in Japanese). Proceedings of the 14th Annual Meeting of the Japanese Society for Psoriasis Research 1999;14:79–80.
20.
Ogawa F, Nishimura K, Shimizu K, et al: A case of interstitial pneumonia with bullous pemphigoid caused by minocycline, which presented in an apparently curable state of psoriasis vulgaris (in Japanese). Nishinihon J Dermatol 1999;61:576–9.
21.
Hinoue A, Takimoto R, Kawai M, et al: A case of psoriasis vulgaris associated with bullous pemphigoid (in Japanese). Proceedings of the16th Annual Meeting of the Japanese Society for Psoriasis Research 2001;16:141–142.
22.
Konohana I, Kobayashi S: A case of pustular psoriasis later associated with bullous pemphigoid (in Japanese). Jpn J Clin Dermatol 2001;55:608–610.
23.
Kawashima T, Kodama K, Hayashi H, et al: A case of psoriasis vulgaris developing bullous pemphigoid (in Japanese). Proceedings of the16th Annual Meeting of the Japanese Society for Psoriasis Research 2001;16:138.
24.
Momosaki N, Yasumoto S, Hashimoto T: A case of psoriasis vulgaris associated with bullous pemphigoid (in Japanese). Proceedings of the16th Annual Meeting of the Japanese Society for Psoriasis Research 2001;16:139–40.
25.
Ishikawa T, Suzuki T, Nobusaki M, et al: A case of bullous pemphigoid associated with psoriasis vulgaris (in Japanese). Jpn J Dermatol 2003;113:759.
26.
Kawahara Y, Zillikens D, Yancey KB, et al: Subepidermal blistering disease with autoantibodies against a novel dermal 200-kD antigen. J Dermatol Sci 2000;23:93–102.
27.
Zillikens D, Ishiko A, Jonkman MF, et al: Autoantibodies in anti-p200 pemphigoid stain skin lacking laminin 5 and type VII collagen. Br J Dermatol 2000;143:1043–1044.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.